Marmarelis Vasilis, Billinger Sandy, Joe Elizabeth, Shin Dae, Hashem Suhaib, Rizko Jasmin, Hazen Emily, Cardim Danilo, Burns Jeff, Zhang Rong, Chui Helena C
Biomedical Enginering Department University of Southern California Los Angeles California USA.
Department of Neurology Kansas University Medical Center Kansas City Kansas USA.
Alzheimers Dement (Amst). 2025 Jul 18;17(3):e70134. doi: 10.1002/dad2.70134. eCollection 2025 Jul-Sep.
A novel physio-marker, termed "cerebrovascular dynamics index" (CDI), was developed and evaluated in a multi-center National Institutes of Health (NIH)-funded study for improved diagnosis of mild cognitive impairment (MCI) and its transition to Alzheimer's disease (AD).
The CDI quantifies the regulation dynamics of cerebral perfusion and oxygenation (which adjust autonomously blood flow and oxygen delivery over time) through predictive dynamic modeling using relevant time-series data.
Cross-sectional results demonstrated excellent diagnostic performance of CDI in differentiating 90 MCI/AD patients from 77 controls (area under the curve (AUC) = 0.96), which surpassed the commonly used biomarker of amyloid positron emission tomography-standardized uptake value ratio (PET-SUVR) (AUC = 0.78) or cognitive screening tests of Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) (AUC = 0.91 and 0.92, respectively). The CDI can also be used for disease staging because it differentiated 56 MCI from 34 mild AD participants (AUC = 0.98).
These findings offer the promise of a high-performance diagnostic physio-marker for MCI and AD, which can be obtained in a comfortable, rapid, and automated manner in clinical settings.
Novel physio-marker (cerebrovascular dynamics index [CDI]) quantifies the regulation dynamics of cerebral perfusion.The CDI was shown to improve mild cognitive impairment/Alzheimer's disease (MCI/AD) diagnosis (area under the curve [AUC] >0.95) relative to existing markers.The CDI is obtained non-invasively, objectively, rapidly, and inexpensively.The CDI performance supports the key role of cerebrovascular dysfunction in AD.The CDI is obtained via dynamic modeling of hemodynamic/oxygenation time-series data.
在一项由美国国立卫生研究院（NIH）资助的多中心研究中，开发并评估了一种名为“脑血管动力学指数”（CDI）的新型生理标志物，用于改善轻度认知障碍（MCI）及其向阿尔茨海默病（AD）转变的诊断。
CDI通过使用相关时间序列数据的预测动态模型，量化脑灌注和氧合的调节动态（其随时间自动调节血流和氧气输送）。
横断面结果显示，CDI在区分9名MCI/AD患者和77名对照者方面具有出色的诊断性能（曲线下面积[AUC]=0.96），超过了常用的淀粉样蛋白正电子发射断层扫描标准化摄取值比率（PET-SUVR）生物标志物（AUC=0.78）或简易精神状态检查表（MMSE）和蒙特利尔认知评估量表（MoCA）的认知筛查测试（AUC分别为0.91和0.92）。CDI还可用于疾病分期，因为它区分了56名MCI患者和34名轻度AD参与者（AUC=0.98）。
这些发现为MCI和AD提供了一种高性能诊断生理标志物的前景，该标志物可在临床环境中以舒适、快速和自动化的方式获得。
新型生理标志物（脑血管动力学指数[CDI]）量化脑灌注的调节动态。相对于现有标志物，CDI被证明可改善轻度认知障碍/阿尔茨海默病（MCI/AD）诊断（曲线下面积[AUC]>0.95）。CDI通过非侵入性、客观、快速且廉价的方式获得。CDI的性能支持脑血管功能障碍在AD中的关键作用。CDI通过血流动力学/氧合时间序列数据的动态模型获得。
